PMID- 37749096
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20240218
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Sep 25
TI  - Zinc nanoparticles ameliorated obesity-induced cardiovascular disease: role of 
      metabolic syndrome and iron overload.
PG  - 16010
LID - 10.1038/s41598-023-42550-y [doi]
LID - 16010
AB  - Obesity is a complicated disease characterized by abundant fat accumulation. It 
      is associated with cardiovascular disease. The current study aimed to appreciate 
      the role of synthesized zinc oxide nanoparticles (ZnONPs) (18.72 nm in size) in 
      curbing cardiovascular disease in an obesity model of a high fat/sucrose diet in 
      male rats. For 16 weeks, 24 rats were fed a high-fat diet and a 25% sucrose 
      solution to develop obesity, and after that, the rats were randomly allocated 
      into four groups of rats. Group 1 served as the control group and consisted of 
      normal, non-obese rats. Group 2 comprised obese rats that were injected with an 
      equivalent volume of a neutral substance, serving as vehicle control. In Group 3 
      or 4, obese rats were treated with an intraperitoneal injection of 5 or 10mg/kg 
      of zinc oxide nanoparticles (ZnONPs) for eight weeks. The treatment of obese rats 
      with ZnONPs decreased plasma levels of monocyte chemoattractant Protein-1 
      (MCP-1), resistin, ENA78, tumor necrosis factor-alpha (TNF-alpha), interleukin 6 
      (IL6), and C reactive protein (CRP). Also, the remediation of obese rats with 
      ZnONPs led to a significant decrease in body mass index (BMI), body weight gain, 
      leptin, cholesterol, triglycerides, LDL (Low-density lipoprotein), glucose, and 
      insulin resistance index (HOMA-IR). Moreover, ZnONPs treatment lowered troponin, 
      creatine phosphokinase-MB (CK-MB), lactate dehydrogenase (LDH), cardiac or 
      adipose tissue iron content, and malondialdehyde (MDA) either in blood or heart 
      tissue. Otherwise, treating obese rats with ZnONPs enhanced plasma adiponectin 
      levels, cardiac-reduced glutathione (GSH), and superoxide dismutase (SOD). In 
      addition, ZnONPs displayed a significant influence on the cardiovascular system 
      since they combat the rise in blood pressure and the pathological changes of the 
      heart and aorta besides maintaining plasma nitric oxide levels. The results 
      showed a positive correlation between BMI and MDA, MPC-1, CK-MB, and LDH. ZnONPs 
      are convenient in treating cardiovascular disease in obese rats via reduced blood 
      pressure, oxidative stress, cardiac iron accumulation, insulin resistance, and 
      inflammatory markers.
CI  - (c) 2023. Springer Nature Limited.
FAU - Bashandy, Samir A E
AU  - Bashandy SAE
AD  - Pharmacology Department, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 
      12622, Cairo, Egypt.
FAU - El-Seidy, Ahmed M A
AU  - El-Seidy AMA
AD  - Inorganic Chemistry Department, National Research Centre, 33 El-Bohouth St., 
      Dokki, P.O. 12622, Cairo, Egypt.
FAU - Ibrahim, Fatma A A
AU  - Ibrahim FAA
AD  - Biophysics Group, Department of Biochemistry, National Research Centre, 33 
      El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt.
FAU - Abdelrahman, Sahar S
AU  - Abdelrahman SS
AD  - Pathology Department, Faculty of Veterinary Medicine, Cairo University, Cairo, 
      Egypt.
FAU - Abdelmottaleb Moussa, Sherif A
AU  - Abdelmottaleb Moussa SA
AD  - Inorganic Chemistry Department, National Research Centre, 33 El-Bohouth St., 
      Dokki, P.O. 12622, Cairo, Egypt.
FAU - ElBaset, Marawan A
AU  - ElBaset MA
AUID- ORCID: 0000-0002-0861-6251
AD  - Pharmacology Department, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 
      12622, Cairo, Egypt. dr.marawan@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230925
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - J41CSQ7QDS (Zinc)
RN  - SOI2LOH54Z (Zinc Oxide)
RN  - E1UOL152H7 (Iron)
SB  - IM
EIN - Sci Rep. 2024 Feb 14;14(1):3746. PMID: 38355658
MH  - Male
MH  - Animals
MH  - Rats
MH  - *Metabolic Syndrome/complications
MH  - Zinc
MH  - *Zinc Oxide
MH  - *Cardiovascular Diseases/etiology
MH  - *Insulin Resistance
MH  - *Metal Nanoparticles
MH  - Obesity/complications
MH  - *Iron Overload/complications/drug therapy
MH  - Iron
PMC - PMC10519991
COIS- The authors declare no competing interests.
EDAT- 2023/09/26 00:42
MHDA- 2023/09/27 06:42
PMCR- 2023/09/25
CRDT- 2023/09/25 23:17
PHST- 2023/02/18 00:00 [received]
PHST- 2023/09/12 00:00 [accepted]
PHST- 2023/09/27 06:42 [medline]
PHST- 2023/09/26 00:42 [pubmed]
PHST- 2023/09/25 23:17 [entrez]
PHST- 2023/09/25 00:00 [pmc-release]
AID - 10.1038/s41598-023-42550-y [pii]
AID - 42550 [pii]
AID - 10.1038/s41598-023-42550-y [doi]
PST - epublish
SO  - Sci Rep. 2023 Sep 25;13(1):16010. doi: 10.1038/s41598-023-42550-y.